Serum Institute of India has said it will begin testing the Kovovax vaccine to protect children from Covid 19 in July. The US vaccine development company Novavax, after testing children in the US, said its phase 3 trial in 119 cities in the US state of Mexico has shown very good results, with a percentage of 90 , 4%.
The Pune-based Serum Institute of India will begin vaccine trials on children in July. The institute will test the Novavax vaccine for children, which was developed by a US-based biotechnology company known as Kovovax in India. Serum is a partner of Novavax and is considering the possibility of launching Kovovax in India by September. The US vaccine development company Novavax, after testing children in the US, said its phase 3 trial in 119 cities in the US state of Mexico has shown very good results, with a percentage of 90 , 4%.
Is Novavax Baccine safe?
A day after the US company released the data from Novavax, Dr VK Paul, head of the Kovid-19 task force in India, said the published data shows that Novavax is a safe vaccine, he said. : “From the available data We are learning that the vaccine is extremely safe. But most importantly, the Serum Institute of India will produce this effective vaccine for children in India. He also said the serum should begin its trial on children without any delay.
Bharat Biotech and Zydus Cadila also conduct clinical trials
Bharat Biotech has started clinical trials of Covaccine on 12-18 year olds. This trial will be carried out on a total of 525 children at AIIMS Patna and Delhi. Along with this, Zydus Cadila has also started the clinical trial of his Kovid vaccine for 12-18 year olds. The pharmaceutical company is also planning a clinical trial in children aged 5 to 12.
This is why the Kovovax trial is important.
The government expects 200 million doses of this vaccine to be available by August and December. Other than that, Kovovax can be stored at a temperature of 2-8 degrees and this is a huge aspect of keeping it in India and is very beneficial for the cold chain in India. Second, to make the Novavax vaccine, recombinant nanoparticle technology was used, which is already tested and from this antigen is generated. It is driven by the spike protein of the corona virus. Similar technology has been used in the preparation of vaccines against HPV, hepatitis and influenza in humans.
America had given Pfizer’s vaccine the green signal for children up to 12 years old, on that issue, when asked if India was considering procuring this vaccine as well, Dr Paul said the India 25-26 crore doses will be needed for immunization of children in India. He said now to decide which vaccine will be used on children, so remember this, the age group of children here is also very large. The number of children in the 12-18 age group is estimated to be 13-14 crore.
